Form 4: TriSalus Life Sciences Executive Jodi Devlin Reports Stock Transactions
SEC Filing
Jodi Devlin, Chief of Clinical Operations at TriSalus Life Sciences, reports acquisition and disposal of common stock related to vested RSUs.
Summary
- Jodi Devlin, Chief of Clinical Operations at TriSalus Life Sciences, filed a Form 4 detailing changes in beneficial ownership.
- On May 19, 2025, Devlin acquired 24,131 shares of common stock at $5.18 per share through the vesting of Restricted Stock Units (RSUs).
- On the same day, Devlin sold 4,764 shares of common stock at $5.18 per share to cover the tax liability associated with the vested RSUs.
- Following these transactions, Devlin beneficially owns 52,764 shares of TriSalus Life Sciences common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the impact is likely minimal given the relatively small number of shares involved.
Key Dates
| Date | Description |
|---|---|
| 05/19/2025 | Date of stock acquisition and disposal. |
| 05/21/2025 | Date of signature by Attorney-in-Fact. |
Keywords
Form 4, Beneficial Ownership, TriSalus Life Sciences, Stock Transaction, Jodi Devlin, TLSI, RSU
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.